When does the Fasenra (benralizumab) patent expire in Europe?
Patent timing for benralizumab in Europe depends on which specific form of protection you mean (active-substance patent, formulation/use patents, or supplementary protection such as SPCs). The provided information does not include the relevant European patent numbers, SPC status, or the expiry dates for Fasenra, so the exact expiry date cannot be confirmed here.
Can biosimilars launch in Europe before patent expiry?
In Europe, a biosimilar’s commercial launch can be blocked by enforceable patents even if regulatory approval is possible. Typically, the first question is whether the biosimilar company can obtain regulatory approval but delay “entry on the market” until patent barriers lift. The key details that determine this for benralizumab would be:
- which patents (and any SPCs) are in force in each country
- which biosimilar applicants are sued or covered by court decisions or settlement terms
- whether the biosimilar company enters “at risk” (launching despite active litigation)
Those patent and litigation specifics are not included in the provided information, so the launch timing can’t be pinned down.
What timelines matter most: regulatory approval vs. market entry?
For European launches, two timelines often diverge:
- Regulatory approval (EMA) can be granted if quality, safety, and efficacy requirements are met.
- Market entry can be delayed by patent/SPC protection and enforcement actions.
So even if an EMA decision occurs, the competitive reality may still wait for patent expiry or for legal resolution/settlement.
Which benralizumab biosimilar could launch first in Europe?
The answer depends on which biosimilar applicants have progressed through EMA assessment, and then on patent status and enforcement in specific European countries. The provided information does not identify:
- named benralizumab biosimilars
- their EMA authorization dates
- their intended launch countries
- any related litigation or settlements
What should patients and prescribers expect if a biosimilar launches?
In practice, once a biosimilar is commercially available, the main patient-facing questions are usually:
- whether the biosimilar has the same indication coverage and dosing schedule as Fasenra
- whether switching is supported in local prescribing guidance
- what happens if a patient is stable on the reference product
Exact switching guidance and interchangeability rules vary by country and are not covered in the provided information.
What information you can share so the expiry/launch date can be determined precisely
If you want a concrete Europe expiry and likely launch window, share any of the following (even one helps):
- the specific European patent number(s) or an SPC number for benralizumab/Fasenra
- a country focus (EU-wide is not enough for enforcement; UK, DE, FR, etc. can differ)
- whether you mean “first generic entry,” “biosimilar market entry,” or “end of SPC”
- the name of the benralizumab biosimilar you’re tracking
Sources
No sources were provided in the prompt, so no citations can be listed.